In addition to the basic intellectual property standards set out in the TRIPS agreement, many nations have committed to bilateral agreements to adopt a higher level of protection. This collection of standards, known as TRIPS or TRIPS-Plus, can take many forms.  The general objectives of these agreements are: the conditions of the plus members, which impose standards beyond the trips, have also been examined.  These free trade agreements contain conditions that limit the ability of governments to introduce competition for generic drug manufacturers. In particular, the United States has been criticized for promoting protection far beyond the standards prescribed by the TRIPS. The U.S. free trade agreements with Australia, Morocco and Bahrain have expanded patentability by making patents available for new uses of known products.  The TRIPS agreement authorizes the granting of compulsory licences at the discretion of a country. The terms of trips plus in the U.S. Free Trade Agreement with Australia, Jordan, Singapore and Vietnam have limited the application of mandatory licences to emergencies, remedies for cartels and abuse of dominance, and cases of non-commercial public use.
 The TRIPS agreement introduced intellectual property rights into the multilateral trading system for the first time and remains the largest multilateral agreement on intellectual property to date. In 2001, developing countries, fearing that developed countries had insisted on too narrow a reading of the TRIPS trip, launched a series of discussions that culminated in the Doha Declaration. The Doha Declaration is a WTO DECLARATION that clarifies the scope of the TRIPS agreement, which states, for example, that TRIPS can and should be interpreted in light of the objective of “promoting access to medicines for all”. Unlike other IP agreements, TRIPS have an effective enforcement mechanism. States can be disciplined by the WTO dispute settlement mechanism. The agreement on aspects of intellectual property rights that affect WTO trade is commonly referred to as the TRIPS Agreement or simply as TRIPS. TRIPS is one of the most important agreements that includes the World Trade Organization (WTO) agreement. This agreement was negotiated as part of the eighth round of multilateral trade negotiations from 1986-1994 under the General Agreement on Tariffs and Trade (GATT), commonly known as the Uruguay Round, which runs from 1986 to 1994.
It appears as Annex 1 C of the Marrakesh Agreement, which is the name of the main WTO agreement. The Uruguay Round introduced intellectual property rights into the multilateral trading system for the first time through a range of broad disciplines. The TRIPS agreement is part of the “single commitment” resulting from the Uruguay Round negotiations. This means that the TRIPS agreement is mandatory for all WTO members. It also means that the provisions of the agreement are governed by the WTO Dispute Settlement Mechanism, which is contained in the Dispute Settlement Agreement (“Agreement on Dispute Settlement Rules and Procedures”). The TRIPS agreement is one of the most important agreements in the WTO. An agreement reached in 2003 relaxed domestic market requirements and allows developing countries to export to other countries with a public health problem as long as exported drugs are not part of a trade or industrial policy.  Drugs exported under such regulations may be packaged or coloured differently to prevent them from affecting the markets of industrialized countries. Since the TRIPS agreement came into force, it has been criticized by developing countries, scientists and non-governmental organizations. While some of this criticism is generally opposed to the WTO, many proponents of trade liberalization also view TRIPS policy as a bad policy. The effects of the concentration of wealth in TRIPS (people`s money in countries)